A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
In 1916, Popielski described histamine as a gastric secretagogue of hydrochloric acid. William Beaumont was an army surgeon who in 1825, was able to observe digestion as it took place in the stomach. This was made possible by experiments on a man with a stomach wound that did not fully heal leaving an opening into the stomach. The churning motion of the stomach was described among other findings. In the 19th century, it was accepted that chemical processes were involved in the process of digestion. Physiological research into secretion and the gastrointestinal tract was pursued with experiments undertaken by Claude Bernard, Rudolph Heidenhain and Ivan Pavlov. The rest of the 20th century was dominated by research into enzymes. The first to be discovered was secretin by Ernest Starling in 1902, with ensuing results from John Edkins in 1905 who first suggested gastrin with its structure being determined in 1964. Andre Latarjet and Lester Dragstedt found a role for acetylcholine in the digestive system. In 1972, H2 receptor agonists were described by J. Black, that block the action of histamine and decrease the production of hydrochloric acid. In 1980, proton pump inhibitors were described by Sachs. In 1983, the role of Helicobacter pylori in the formation of ulcers was described by Barry Marshall, and Robin Warren. Art historians have often noted that banqueters on iconographic records of ancient Mediterranean societies almost always appear to be lying down on their left sides. One possible explanation could lie in the anatomy of the stomach and in the digestive mechanism.
During World War I Hahn served with a Landwehr regiment on the Western Front, and with the chemical warfare unit headed by Fritz Haber on the Western, Eastern and Italian fronts, earning the Iron Cross (2nd Class) for his part in the First Battle of Ypres. After the war he became the head of the KWIC, while remaining in charge of his own department. Between 1934 and 1938, he worked with Strassmann and Meitner on the study of isotopes created by neutron bombardment of uranium and thorium, which led to the discovery of nuclear fission. He was an opponent of Nazism and the persecution of Jews by the Nazi Party that caused the removal of many of his colleagues, including Meitner, who was forced to flee Germany in 1938. Nonetheless, during World War II, he worked on the German nuclear weapons program, cataloguing the fission products of uranium. At the end of the war he was arrested by the Allied forces and detained in Farm Hall with nine other German scientists, from July 1945 to January 1946. Hahn served as the last president of the Kaiser Wilhelm Society for the Advancement of Science in 1946 and as the founding president of its successor, the Max Planck Society from 1948 to 1960. In 1959, he co-founded the Federation of German Scientists, a non-governmental organisation committed to the ideal of responsible science. As he worked to rebuild German science, he became one of the most influential and respected citizens of post-war West Germany.
Male mammals typically have rudimentary mammary glands and nipples, with a few exceptions: male mice do not have nipples, male marsupials do not have mammary glands, and male horses lack nipples. The male dayak fruit bat has lactating mammary glands. Male lactation occurs infrequently in some species. Mammary glands are true protein factories, and several labs have constructed transgenic animals, mainly goats and cows, to produce proteins for pharmaceutical use. Complex glycoproteins such as monoclonal antibodies or antithrombin cannot be produced by genetically engineered bacteria, and the production in live mammals is much cheaper than the use of mammalian cell cultures.
Ion mobility spectrometry (IMS) is a technique of ion separation in gaseous phases based on their differences in ion mobility when an electric field is applied providing spatial separation prior to MS analysis. With the introduction of DESI as an ion source for ion mobility mass spectrometry, applications for IMS have expanded from only vapor-phase samples with volatile analyses to also intact structures and aqueous samples. When coupled to a time-of-flight mass spectrometer, analysis of proteins is also possible. These techniques work in tandem to one another to investigate ion shapes and reactiveness after ionization. A key characteristic of this setup is its ability to separate the distribution of ions generated in DESI prior to mass spectrometry analysis.
Rockefeller Benjamin Jealous (1994), president of the NAACP Ai-jen Poo (1996), activist, recipient of the MacArthur Fellowship in 2014 Risë Wilson (1997), activist Anna Baltzer (2002), activist for Palestinian human rights Ady Barkan (2006), activist and organizer for Center for Popular Democracy Tourmaline (2006), activist and filmmaker Emma Sulkowicz (2015), performance activist known for Mattress Performance (Carry That Weight) and Ceci N'est Pas Un Viol Coleman Hughes (2020), activist and writer on issues of race and racism Henry Williams (2022), political activist and chief of staff of the Mike Gravel 2020 presidential campaign
Sources: en.wikipedia.org
== Top CROs by annual revenue == As of 2016, there was a 15.5% increase in R&D spending from 2015 to 2020. The list of contract research organizations includes the following notable companies worldwide:
This is a list of investigational panic disorder drugs, or drugs that are currently under development for clinical use for the treatment of panic disorder (PD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
=== Lupus === As of 2016, studies in cells, animals, and humans have suggested that mTOR activation is a process underlying systemic lupus erythematosus and that inhibiting mTOR with rapamycin may be a disease-modifying treatment. As of 2016 rapamycin had been tested in small clinical trials in people with lupus.
In mammals, methylation occurs in the liver by methyltransferases, the products being the dimethylarsinous acid ((CH3)2AsOH) and dimethylarsinic acid ((CH3)2As(O)OH), which have the oxidation states As(III) and As(V), respectively. Although the mechanism of methylation of arsenic in humans has not been elucidated, the source of methyl is methionine, which suggests a role of S-adenosyl methionine. Exposure to toxic doses begin when the liver's methylation capacity is exceeded or inhibited. There are two major forms of arsenic that can enter the body, arsenic (III) and arsenic (V). Arsenic (III) enters the cells though aquaporins 7 and 9, which is a type of aquaglyceroporin. Arsenic (V) compounds use phosphate transporters to enter cells. The arsenic (V) can be converted to arsenic (III) by the enzyme purine nucleoside phosphorylase. This is classified as a bioactivation step, as although arsenic (III) is more toxic, it is more readily methylated. There are two routes by which inorganic arsenic compounds are methylated. The first route uses Cyt19 arsenic methyltransferase to methylate arsenic (III) to a mono-methylated arsenic (V) compound. This compound is then converted to a mono-methylated arsenic (III) compound using Glutathione S-Transferase Omega-1 (GSTO1). The mono-methylated arsenic (V) compound can then be methylated again by Cyt19 arsenic methyltransferase, which forms a dimethyl arsenic (V) compound, which can be converted to a dimethyl arsenic (III) compound by Glutathione S-Transferase Omega-1 (GTSO1).
=== First endosymbiosis === Eukaryotic algae are polyphyletic thus their origin cannot be traced back to a single hypothetical common ancestor. It is thought that they came into existence when photosynthetic coccoid cyanobacteria got phagocytized by a unicellular heterotrophic eukaryote (a protist), giving rise to double-membranous primary plastids. Such symbiogenic events (primary symbiogenesis) are believed to have occurred more than 1.5 billion years ago during the Calymmian period, early in Boring Billion, but it is difficult to track the key events because of so much time gap. Primary symbiogenesis gave rise to three divisions of archaeplastids, namely the Viridiplantae (green algae and later plants), Rhodophyta (red algae) and Glaucophyta ("grey algae"), whose plastids further spread into other protist lineages through eukaryote-eukaryote predation, engulfments and subsequent endosymbioses (secondary and tertiary symbiogenesis). This process of serial cell "capture" and "enslavement" explains the diversity of photosynthetic eukaryotes. The oldest undisputed fossil evidence of eukaryotic algae is Bangiomorpha pubescens, a red alga found in rocks around 1047 million years old.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.